| Followers | 372 |
| Posts | 12575 |
| Boards Moderated | 0 |
| Alias Born | 04/23/2006 |
Tuesday, April 21, 2015 7:01:59 PM
And you think the fact that it went down to .035 today changes the fact that PPCH will hit .2 sometime in the next few months.
My first buy in January was at .006, then it went down to .002 and I pounded the ask for millions and millions of shares, before it took off to .10.
If I followed your logic I wouldn't have 11M shares of PPCH with an average sub-penny.
Again, thanks for helping us get some more cheapies, lolzzz ;)
My first buy in January was at .006, then it went down to .002 and I pounded the ask for millions and millions of shares, before it took off to .10.
If I followed your logic I wouldn't have 11M shares of PPCH with an average sub-penny.
Again, thanks for helping us get some more cheapies, lolzzz ;)
Recent PPCB News
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:18 AM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 04/10/2026 09:29:59 PM
- Form DEF 14C - Other definitive information statements • Edgar (US Regulatory) • 03/31/2026 10:12:48 AM
- Propanc Biopharma Executes Multi-Yr, Anti-Aging & Cancer Research Collaboration with the Universities of Jaén and Granada, Spain • GlobeNewswire Inc. • 03/24/2026 12:45:00 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 03/19/2026 09:30:42 PM
- Propanc Biopharma Targets $3B+ Pancreatic Cancer Market with PRP: 85%+ Tumor Inhibition in Breakthrough Proenzyme Therapy • GlobeNewswire Inc. • 03/12/2026 12:45:00 PM
- Propanc Biopharma Executes Service Agreement with FyoniBio to Establish & Validate Pharmacokinetics Assay for Phase 1b First-In-Human Study • GlobeNewswire Inc. • 03/10/2026 12:45:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 03/06/2026 10:22:19 PM
- Propanc Biopharma Spotlights PRP as Potential Breakthrough for Metastatic Solid Tumors • IH Market News • 03/03/2026 03:34:06 PM
- Propanc Biopharma’s Lead Asset PRP Shows >85% Tumor Growth Inhibition in Preclinical Pancreatic Models • GlobeNewswire Inc. • 03/03/2026 01:45:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/26/2026 10:19:30 PM
- Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 02/19/2026 10:28:16 PM
- Propanc Biopharma Provides Corporate Update and Reports Half Yearly 2025/26 Results • GlobeNewswire Inc. • 02/18/2026 01:45:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/17/2026 07:54:17 PM
- Propanc Biopharma Unveils PRP: A Game-Changing Proenzyme Therapy Poised to Challenge Standard Cancer Treatments in the $3+ Billion Pancreatic Cancer Market • GlobeNewswire Inc. • 02/05/2026 01:45:00 PM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 02/02/2026 10:29:59 PM
- Propanc Biopharma Accelerates IP Momentum: Files Fourth Provisional Patent Application in Just Two Months – Strengthening Global Protection for Breakthrough Proenzyme Formulations • GlobeNewswire Inc. • 01/27/2026 01:45:00 PM
- Propanc Biopharma Files New Provisional Patent Application for Methods of Producing Trypsinogen & Chymotrypsinogen with IP Australia • GlobeNewswire Inc. • 01/20/2026 01:45:00 PM
- Propanc Biopharma Explains How PRP Could Impact Pancreatic Cancer • GlobeNewswire Inc. • 01/15/2026 01:45:00 PM
- Propanc Biopharma Provides Shareholder Update • GlobeNewswire Inc. • 01/13/2026 01:45:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/07/2026 10:00:52 PM
- Form DEF 14C - Other definitive information statements • Edgar (US Regulatory) • 12/29/2025 10:13:52 PM
- Propanc Biopharma Publishes Impact of Proenzymes on Pancreatic Ductal Adenocarcinoma Fibroblasts in Peer Reviewed Journal • GlobeNewswire Inc. • 12/22/2025 12:00:00 PM

